Omar Alomari: Our New Publication on Apixaban vs Rivaroxaban for VTE
Omar Alomari, Co-Founder of Clinalyst, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Internal and Emergency Medicine, adding:
“Pleased to announce our new paper published in Internal and Emergency Medicine.
‘Apixaban vs rivaroxaban for venous thromboembolism: a systematic review and meta-analysis’.
Evaluating 13 studies and over 220,000 patients with VTE. Overall, apixaban demonstrated a more favorable risk-benefit profile in VTE management.
Huge thanks to my friend Bassel Alrabadi , for the great collaboration (we made this paper in 1 week).
Title: Apixaban vs rivaroxaban for venous thromboembolism: a systematic review and meta-analysis
Authors: Bassel Alrabadi, Omar Alomari, Alwaleed Emad Alshakhshir, Shahad S. Abdelwahab, Natalie Bandak
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 11, 2026, 22:40Bahram Alamdary Badlou: Platelets as First Responders in Hemostasis, Immunity, and Inflammation
-
Oct 11, 2026, 22:22Vipin Singh: New Publication on Hippo-YAP Signaling and Platelet Activation
-
Oct 11, 2026, 22:21Trygve Berge: New AFNOR Paper on AF-related Stroke in Norway
-
Oct 11, 2026, 21:22Shayan Roshan: Happy to Share Two Research Milestones in Trauma Care and Pancreatic Cancer
-
Oct 11, 2026, 21:16Chokri Ben Lamine: Anemia in Myelofibrosis – Multiple Mechanisms, Limited Responses
-
Oct 11, 2026, 21:03Carmela Walker: Supporting Warriors Living With SCD Through Dental Care and Advocacy
-
Oct 11, 2026, 21:00Rishdha Roshad: Intraoperative Cell Salvage – Turning Blood Loss into an Opportunity for Recovery
-
Oct 11, 2026, 20:59Anthony R. Sloan: Honored to Share Our Work at the 20th Midwest Platelet Conference
-
Oct 11, 2026, 20:55Vipin M. Vashishtha: Mild COVID-19 and Malaria Leave Measurable Fingerprints on the Clotting System